Enregistrement :
9
de
11
(2015-08-31
à
2016-10-11)
Politique ou Programme
Industry Canada's Science & Technology strategy regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Patented Medicine Prices Review Board regarding claims of jurisdiction with respect to generic drug products associated with a patent.
Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions
Provide input into guidance with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders.
Provide input into policy discussions regarding the potential development of a national pharmacare program governments.
Providing input into the development and implementation of an approval pathway for Subsequent Entry Biologics by Health Canada.
To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat counterfeit pharmaceutical both nationally and globally.
participation in consultations, providing comments on modernization of the Food and Drugs Act and related regulations regarding pharmaceuticals
Proposition législative, Projet de loi ou résolution
Provide input into the Government of Canada's negotiations regarding the Anti-Counterfeiting Trade Agreement and bilateral trade agreements with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic Trade Agreement with respect to pharmaceuticals, counterfeit medicines, border measures, and intellectual property.
Règlement
The need for amendments to the Patented Medicines (Notice of Compliance) Regulations of the Patent Act and address operational concerns such as bringing finality to proceedings under the Regulations; allowing generic manufacturers to amend a Notice of Allegation; and providing meaningful damages and other disincentives to discourage abuse of the Regulatioins by brand name manufacturers.